NV-SHARP
19.12.2022 15:01:35 CET | Business Wire | Press release
Sharp Corporation (TOKYO:6753) is set to return to CES 2023 with an advanced technologies and products that embody the company’s ESG-focused management under the four themes of New Energy, Automotive, AR/VR, and TV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005001/en/
(Graphic: Business Wire)
Location of Sharp Booth:
Petrus Ballroom, Wynn Las Vegas Hotel
3131 Las Vegas Blvd., Las Vegas, NV 89109, U.S.A.
Exhibit Dates and Time:
January 5 to January 8, 2023 (Thursday to Sunday); 10 a.m. – 5 p.m.
Sharp will unveil for the first time outside of Japan the LC-LH (Liquid and Crystal Light Harvesting), an indoor photovoltaic device developed by integrating dye-sensitized solar cells and LCD technology. Sharp will also exhibit perovskite solar cells, which are attracting attention as the next generation of solar cells.
Passenger Information Display utilizing viewing angle control will be introduced as advanced automotive devices. Compound photovoltaic module with the world’s highest*1 conversion efficiency is expected to be installed on vehicles such as EVs, as well as used in aerospace and aviation applications.
Ultra-lightweight head-mounted displays prototype for VR equipped with its latest devices, such as an ultra-high-resolution display, ultra-high-speed autofocus camera, and ultra-compact proximity sensor would be displayed at AR/VR corner.
Visitors can experience a new generation of images with outstanding brightness and color expression created by mini LED backlighting and quantum-dot technology for the flagship AQUOS XLED TV model for the global market. In addition, Sharp will unveil a prototype of one of the world’s largest*2 120-inch model*3 for the first time.
About Sharp
Sharp Corporation is a worldwide developer of innovative products and core technologies that play a key role in shaping the future of electronics. Also with high technology at their core, Sharp have developed many “world-first”, “Japan-first”, and “industry-first”, hardware and devices. Being the origin of countless innovations, through these developments, Sharp will continue to revolutionize the world. Sharp Corporation employs 48,165 people around the world (as of September 30, 2022) and recorded consolidated annual sales of 2.5 trillion yen for the fiscal year ended March 31, 2022.
*1 As of December 15, 2022, for photovoltaic modules at the research level (according to Sharp findings) |
*2 As of December 15, 2022, for LCDs equipped with mini LED backlights (according to Sharp findings) |
*3 The 120-inch AQUOS XLED is not equipped with a tuner for receiving TV broadcasts. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom